Hot Features
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. The company lead product candidate is TTI-0102, a prodrugs that consists of cysteamine for use in the treatment of mitochondrial encephalopa... Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. The company lead product candidate is TTI-0102, a prodrugs that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and nephropathic cystinosis. The company is headquartered in Toronto, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.03 | 5.55555555556 | 0.54 | 0.57 | 0.54 | 125 | 0.57 | CS |
| 4 | -0.03 | -5 | 0.6 | 0.6 | 0.54 | 10826 | 0.57099158 | CS |
| 12 | -0.02 | -3.38983050847 | 0.59 | 0.64 | 0.51 | 18741 | 0.56987348 | CS |
| 26 | -0.08 | -12.3076923077 | 0.65 | 0.65 | 0.44 | 19202 | 0.55445233 | CS |
| 52 | -0.27 | -32.1428571429 | 0.84 | 0.87 | 0.44 | 20782 | 0.64628061 | CS |
| 156 | -0.07 | -10.9375 | 0.64 | 1.06 | 0.44 | 20054 | 0.68824723 | CS |
| 260 | 0.17 | 42.5 | 0.4 | 1.06 | 0.375 | 19134 | 0.65862521 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.